MENU
+Compare
MCRB
Stock ticker: NASDAQ
AS OF
Dec 20, 04:59 PM (EDT)
Price
$0.92
Change
-$0.00 (-0.00%)
Capitalization
157.39M

MCRB Seres Therapeutics Forecast, Technical & Fundamental Analysis

a developer of novel treatments for diseases related to the human microbiome

Industry Biotechnology
MCRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
a Summary for MCRB with price predictions
Dec 20, 2024

MCRB's RSI Oscillator recovers from overbought zone

The 10-day RSI Indicator for MCRB moved out of overbought territory on December 02, 2024. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 instances where the indicator moved out of the overbought zone. In of the 28 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 47 cases where MCRB's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MCRB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

MCRB broke above its upper Bollinger Band on November 25, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for MCRB entered a downward trend on November 19, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on December 17, 2024. You may want to consider a long position or call options on MCRB as a result. In of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for MCRB just turned positive on December 19, 2024. Looking at past instances where MCRB's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

MCRB moved above its 50-day moving average on November 25, 2024 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for MCRB crossed bullishly above the 50-day moving average on December 02, 2024. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MCRB advanced for three days, in of 268 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MCRB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.536) is normal, around the industry mean (14.556). P/E Ratio (0.000) is within average values for comparable stocks, (87.563). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.739). MCRB has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (1.052) is also within normal values, averaging (256.215).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MCRB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
MCRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

MCRB is expected to report earnings to fall 40.39% to -19 cents per share on March 11

Seres Therapeutics MCRB Stock Earnings Reports
Q4'24
Est.
$-0.20
Q3'24
Missed
by $0.25
Q2'24
Beat
by $0.05
Q1'24
Beat
by $0.07
Q4'23
Beat
by $0.19
The last earnings report on November 13 showed earnings per share of -33 cents, missing the estimate of -7 cents. With 2.79M shares outstanding, the current market capitalization sits at 157.39M.
A.I. Advisor
published General Information

General Information

a developer of novel treatments for diseases related to the human microbiome

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
101 Cambridgepark Drive
Phone
+1 617 945-9626
Employees
233
Web
https://www.serestherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MGHRX59.400.91
+1.56%
Morgan Stanley Inst Growth IR
GDSRX25.030.25
+1.01%
Goldman Sachs Small Cap Eq Insghts R
PDIAX20.330.16
+0.79%
Virtus KAR Equity Income A
MSBWX11.650.09
+0.78%
Morgan Stanley American Resilience C
MFWIX16.050.12
+0.75%
MFS Global Total Return I

MCRB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, MCRB has been loosely correlated with ORMP. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if MCRB jumps, then ORMP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MCRB
1D Price
Change %
MCRB100%
-0.59%
ORMP - MCRB
42%
Loosely correlated
-4.82%
AXON - MCRB
38%
Loosely correlated
+2.60%
AMRN - MCRB
36%
Loosely correlated
-1.18%
ARRY - MCRB
34%
Loosely correlated
+5.43%
ALNY - MCRB
34%
Loosely correlated
+2.75%
More